CYSTIC FIBROSIS TRUST — grant history

Registered charity 1079049 · filings on the Charity Commission register · its own accounts analysis · funder finder · deadlines · watch this funder · check a grantee list

Latest income

£12.0m

Grants listed (FY2025)

Listed grants total

£12.1m

Accounts grants total

£1.4m

listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2025 accounts

What this funder supports

Based on the register classifications and operating areas of the grant recipients we could match to the charity register (a subset of all grantees).

Causes funded

Education/training (3 grantees)
The Advancement Of Health Or Saving Of Lives (3 grantees)
Disability (1 grantee)

Where grantees operate

Throughout England And Wales (2 grantees)
Cardiff (1 grantee)
Northern Ireland (1 grantee)
Scotland (1 grantee)

What changed: FY2024 → FY2025

Grantees that appear, disappear or move by 50%+ between the two most recent filings that have counted grants (unverified reads are left out, so a filing whose grants are all unverified is skipped). A grantee “dropped” may simply have received a multi-year grant earlier.

Change	Grantee	FY2024	FY2025
new	University of Newcastle	—	£800k
new	Royal Brompton Hospital	—	£799k
new	St James’ Hospital	—	£750k
new	Imperial College London	—	£750k
new	University of Nottingham / Queens University Belfast	—	£750k
new	University of Sheffield	—	£749k
new	University of Bristol	—	£748k
new	University College London	—	£375k
up	University of Liverpool	£182k	£375k
down	Newcastle University	£850k	£275k
not listed	Imperial College London / Royal Brompton Hospital	£1.1m	—
not listed	CTAP centres	£436k	—
not listed	Various CF centres	£326k	—
not listed	Medical Research Council	£100k	—
not listed	Innovation Hub Cambridge	£100k	—
not listed	Other Institutions (less than £20k)	£68k	—
not listed	UCL	£50k	—
not listed	Medicines Discovery Catapult Limited	£42k	—

Grants made, per its accounts filings

Download this grant history as CSV (open data, provenance and licence noted in the file).

Recipient	Year	Amount	Purpose
University of Cambridge	FY2025	£800k	SRC028 - Developing better treatments for Mycobacterium abscessus
University of Newcastle	FY2025	£800k	SRC026 - PTSuppress – Novel lead compounds as potential suppressor drugs for CFTR PTC mutations
Royal Brompton Hospital	FY2025	£799k	SRC027 - MATRIARCH_CF – MATeRnal, InfAnt, Reproductive and Child Health in CF
St James’ Hospital	FY2025	£750k	SRC012 - The Impact of Gut Dysbiosis on Lung Inflammation in cystic fibrosis
Imperial College London	FY2025	£750k	SRC015 - TrIFIC: Targeting Immunotherapy for Fungal Infections in cystic fibrosis
Imperial College London	FY2025	£750k	SRC014 - Personalised Approach to Pseudomonas Aeruginosa (PAPA)
University of Newcastle	FY2025	£750k	SRC019 - Mechanisms and measures of the pathways through which cystic fibrosis exocrine pancreatic disease leads to beta-cell dysfunction and diabetes
University of Nottingham / Queens University Belfast	FY2025	£750k	SRC023 - Gut Research Advancing a Mechanistic and Personalised Understanding of Symptoms in cystic fibrosis: A strategic research centre: The GRAMPUS-CF SRC
University of Sheffield	FY2025	£749k	SRC018 - Preventing gastrointestinal cancer in cystic fibrosis
University of Bristol	FY2025	£748k	SRC021 - The CFTR Folding and Function SRC
University of Cambridge	FY2025	£744k	SRC016 - Mucociliary clearance – from fundamentals to personalised treatment
University College London	FY2025	£375k	SRC020 - Therapeutic gene editing of CFTR. Co-funded with CFF
University College London	FY2025	£375k	SRC024 - Restoring the fizz: Pharmacological repair of bicarbonate transport in cystic fibrosis. Co-funded with CFF
University of Liverpool	FY2025	£375k	SRC022 - An evidence-based preclinical framework for the development of antimicrobial therapeutics in cystic fibrosis (PIPE-CF). Co-funded with CFF
University of Sheffield	FY2025	£367k	SRC025 - Pulmonary magnetic resonance imaging for cystic fibrosis. Co-funded with CFF
University of Birmingham	FY2025	£300k	DA003 - Developing autologous stem cell-derived therapies for cystic fibrosis diabetes
Royal Brompton Hospital	FY2025	£300k	DA001 - ADVANCE-CFTR: Advanced Diagnostic Validation and Novel Clinical Evaluation across the CFTR spectrum
Newcastle University	FY2025	£275k	DA004 - Novel role for succinate chemosensing in the pathogenesis of CF airway disease
University of Liverpool	FY2025	£173k	DA002 - ITCH-CF: Investigating The Cardiovascular Health of people living with cystic fibrosis
Imperial College London	FY2025	£100k	VIA116 - Repurposing the multiple sclerosis drug, Glatiramer acetate, to potentiate the action of conventional antibiotics for cystic fibrosis airway infections
Action Medical Research	FY2025	£100k	VIA132 - New therapeutic approaches for treating cystic fibrosis
Our Lady's Children's Hospital	FY2025	£96k	VIA118 - ENHANCE – Establishing Natural History in an Advanced New CF Care Era
University of Nottingham	FY2025	£93k	VIA105 - Core Outcome Set Taskforce for Cystic Fibrosis (COST-CF): a patient-initiated core outcome set for CF
University of Cambridge	FY2025	£75k	VIA130 - AIR max: 3D AIRway organoids to define and MAXimize the efficacy of CFTR gene therapy
Utrecht University, Netherlands	FY2025	£75k	VIA123 - Understanding hypo- and hyper-responding phenotypes of CFTR mutants for therapeutic use
University of Cambridge	FY2025	£65k	VIA128 - Investigating the impact of pathoadaptive mutations on the fitness of Pseudomonas aeruginosa in a polymicrobial airway environment.
University of Cambridge	FY2025	£59k	VIA133 - Characterising the host-pathogen interactions required for intracellular Pseudomonas aeruginosa infection of people with cystic fibrosis
Northumbria University	FY2025	£55k	VIA129 - Impact of respiratory infection antibiotics upon the gut microbiomes of children with CF
University of Nottingham	FY2025	£50k	VIA062 - Scholarship for the National Biofilms Innovation Centre (NBIC)
Ockham Biotech Ltd	FY2025	£50k	VIA117 - Investigating anti-pseudomonal effects of roneparstat, a non-anticoagulant derivative of heparin with multiple anti-microbial, anti-inflammatory and mucolytic activities
Newcastle University	FY2025	£50k	VIA127 - Tracking the mucosal immune response to viral respiratory tract infection in children with cystic fibrosis
University College London	FY2025	£50k	VIA119 - Understanding Regional Lung Physiology in Cystic Fibrosis Using Advanced MRI
Imperial College London	FY2025	£43k	VIA036 - PhD studentship 2 – Air pollution and environmental factors on infection – linking with Registry data
University of Nottingham	FY2025	£38k	VIA107 - Development of a rapid and highly sensitive analytical method for the detection of biomarkers of infection in samples from people with CF
Aston University	FY2025	£25k	VIA098 - Discovery of new and repurposed ß-lactamase inhibitors for improving Mycobacterium abscessus treatment
Bowel Research UK	FY2025	£25k	VIA131 - Optimising bowel cancer screening and surveillance for people with cystic fibrosis: a qualitative study to identify and understand clinician and patient challenges and needs and ways to address these
OmniSpirant Limited	FY2025	£21k	VIA124 - Cell engineering optimisation and electrophysiology assessment of OS001 CFTR Extracellular Vesicles (EVs)
Leeds Beckett University	FY2025	£21k	VIA126 - Cancer risk, screening, and surveillance for people with cystic fibrosis: a national co-designed survey of awareness, perceptions, and behaviours, and information and support needs
London School of Hygiene and Tropical Medicine	FY2025	£18k	VIA121 - Target trial emulation in cystic fibrosis: optimising methods for evaluating long term antibiotic treatment using registry data
University of Liverpool	FY2025	£17k	VIA115 - Postal Sputum Testing for Early Detection of Pseudomonas aeruginosa in CF: POSTED-CF
University of Cambridge	FY2024	£1.2m	Research / Innovation Hub
Imperial College London / Royal Brompton Hospital	FY2024	£1.1m	Research
Newcastle University	FY2024	£850k	Research
CTAP centres	FY2024	£436k	Trial Coordinator commitments made to CTAP centres
Various CF centres	FY2024	£326k	Registry support grants
University of Liverpool	FY2024	£182k	Research
Action Medical Research	FY2024	£105k	Research
Medical Research Council	FY2024	£100k	Research
Innovation Hub Cambridge	FY2024	£100k	Research
Utrecht University, Netherlands	FY2024	£75k	Research
Other Institutions (less than £20k)	FY2024	£68k	Research
UCL	FY2024	£50k	Research
Medicines Discovery Catapult Limited	FY2024	£42k	Research
Leeds Beckett University	FY2024	£21k	Research
OmniSpirant Limited	FY2024	£21k	Research
Queen’s University Belfast	FY2024	£8k	Research
Trial Coordinator commitments made to CTAP centres	FY2023	£953k	Clinical Care
University of Liverpool	FY2023	£753k	Research
Registry support grants made to various CF centres	FY2023	£609k	Clinical Care
Innovation Hub Cambridge	FY2023	£241k	Research
UCL Great Ormond Street	FY2023	£121k	Research
Cystic Fibrosis Canada (Fibrose Kystique) CFC	FY2023	£116k	Research
University of Nottingham	FY2023	£115k	Research
Royal College of Surgeons in Ireland	FY2023	£96k	Research
Medicines Discovery Catapult Limited	FY2023	£81k	Research
Medical Research Council	FY2023	£50k	Research
Newcastle University	FY2023	£50k	Research
University Hospital Llandough	FY2023	£46k	Research
Aston University	FY2023	£28k	Research
Queen’s University Belfast	FY2023	£26k	Research
MDC (CF AMR Syndicate)	FY2023	£20k	Research
Ockham Biotech Limited	FY2023	£17k	Research
Various CF centres	FY2022	£1.6m	Registry support grants
Innovation Hub Cambridge	FY2022	£1.5m	Research grant to University of Cambridge
University of Nottingham	FY2022	£880k	Research grant
University of Liverpool	FY2022	£769k	Research grant
UCL Great Ormond Street	FY2022	£750k	Research grant
University of Bristol	FY2022	£749k	Research grant
CTAP centres	FY2022	£685k	Trial Coordinator commitments
University of Cambridge	FY2022	£365k	Research grant
Queen Elizabeth University Hospital	FY2022	£180k	Research grant
Cystic Fibrosis Canada (Fibrose Kystique) CFC	FY2022	£141k	Research grant
RNID	FY2022	£120k	Research grant
Diabetes UK	FY2022	£105k	Research grant
MDC (CF AMR Syndicate)	FY2022	£95k	Research grant
University of Edinburgh	FY2022	£70k	Research grant
Imperial College London / Royal Brompton Hospital	FY2022	£70k	Research grant
Medicines Discovery Catapult	FY2022	£50k	Research grant
Belfast City Hospital	FY2022	£50k	Research grant
University Hospital Llandough	FY2022	£45k	Research grant
Other Insititutions (less than £20k)	FY2022	£39k	Research grants
Newcastle University	FY2022	£37k	Research grant
University of Copenhagen	FY2022	£27k	Research grant
Aston University	FY2022	£25k	Research grant
The University of Manchester	FY2022	£23k	Research grant
Queen’s University Belfast	FY2022	£21k	Research grant
Various CF centres	FY2021	£1.4m	Registry support grants made to various CF centres (Note 3b)
University of Cambridge/Papworth Hospital	FY2021	£832k	Grant to institutions (Note 3b)
University of Liverpool	FY2021	£769k	Grant to institutions (Note 3b)
St James' University Hospital	FY2021	£750k	The Impact of Gut Dysbiosis on Lung Inflammation in cystic fibrosis
UCL Great Ormond Street	FY2021	£750k	Grant to institutions (Note 3b)
Newcastle University	FY2021	£750k	The Cystic Fibrosis Related Diabetes Strategic Research Centre (CFRD-SRC)
University of Exeter	FY2021	£750k	Physical Activity, Exercise, Sport and Recreation Promotion for Adolescents with CF
Newcastle Univerity	FY2021	£750k	Personalised Therapies for all: Restoring airway function in CF using Alternative Chloride Channels
Imperial College London	FY2021	£750k	Personalised Approach to Pseudomonas aeruginosa (PAPA)
Imperial College London	FY2021	£750k	‘TrIFIC: Targeting Immunotherapy for Fungal Infections in cystic fibrosis’
University of Newcastle	FY2021	£750k	Mechanisms and measures of the pathways through which cystic fibrosis exocrine pancreatic disease leads to beta-cell dysfunction and diabetes
MRC Laboratory of Molecular Biology Cambridge Biomedical Campus	FY2021	£750k	Novel Therapies for Mycobacterium abscessus
University of Bristol	FY2021	£750k	The F508del-CFTR SRC
University of Liverpool	FY2021	£750k	Restoration of luminal fluidity and microbiota in the CF gut (CFGI-SRC)
University of Sheffield	FY2021	£749k	Preventing Gastrointestinal Cancer in cystic fibrosis
University of Bristol	FY2021	£749k	Grant to institutions (Note 3b)
University of Cambridge	FY2021	£749k	Gas, food and lodging; understanding the physiological and metabolic requirements of Pseudomonas aeruginosa in the cystic fibrosis airways
Royal Brompton Hospital	FY2021	£747k	Cystic Fibrosis Epidemiological Network (CF-EpiNet) – Harnessing Data to Improve Lives
University of Cambridge	FY2021	£744k	Mucociliary clearance – from fundamentals to personalised treatment
University College London	FY2021	£740k	Therapeutic gene editing of CFTR
University College London	FY2021	£719k	Personalised Engineered Cell Therapies for cystic fibrosis
St James' University Hospital	FY2021	£371k	Targeting joint disease in cystic fibrosis: identifying therapeutic targets in CF arthropathy
CTAP centres	FY2021	£298k	Trial Coordinator commitments made to CTAP centres (Note 3b)
Queen Elizabeth University Hospital	FY2021	£180k	Grant to institutions (Note 3b)
University Hospital Llandough	FY2021	£120k	Grant to institutions (Note 3b)
Imperial College London	FY2021	£99k	The idealised LCI (i-LCI): Tuning in on the ‘silent years’ of paediatric CF (VIA 068)
Our Lady's Children's Hospital	FY2021	£97k	RECOVER (Real World Clinical Outcomes with Novel Modulator Therapy Combinations in people with CF) (VIA 083)
Imperial College London	FY2021	£90k	RAPID point-of-care infection detection and antibiotic-resistance TESTing enabled with laser-patterned microfluidic devices (RAPID-TEST) (VIA044)
Action Medical Research	FY2021	£90k	Elucidating the structural role of filamentous bacteriophage in Pseudomonas aeruginosa biofilms for disrupting infection in cystic fibrosis airways (VIA051)
University of Nottingham	FY2021	£65k	Gut Imaging for Function & Transit in cystic fibrosis Study 3 (VIA 086)
Imperial College London / Royal Brompton Hospital	FY2021	£56k	Grant to institutions (Note 3b)
University College London	FY2021	£52k	Development of in vitro Transcribed mRNA Therapeutics for cystic fibrosis (VIA063)
University of Nottingham	FY2021	£50k	Scholarship for the National Biofilms Innovation Centre (NBIC) (VIA062)
University College London	FY2021	£50k	Modelling and machine learning to aid the design of CF therapy (VIA 073)
Imperial College London	FY2021	£50k	Exploring the utility of quorum sensing inhibitors and biofilm disruptors on growth and virulence behaviours of Pseudomonas aeruginosa obtained from patients with cystic fibrosis (VIA 085)
Medicines Discovery Catapult	FY2021	£50k	Grant to institutions (Note 3b)
UCL	FY2021	£50k	Quantifying bronchiectasis severity in cystic fibrosis (VIA059)
Imperial College London	FY2021	£50k	Exploring the utility of novel ‘antimicrobial resistance breakers’ on strains of Pseudomonas aeruginosa obtained from patients with cystic fibrosis (VIA052)
Medicines Discovery Catapult	FY2021	£50k	CF AMR Biorepository (VIA 095)
Manchester Metropolitan University	FY2021	£48k	Non-tuberculosis mycobacteria infection and the wider lung microbiota in cystic fibrosis (VIA 078)
Manchester Metropolitan University	FY2021	£47k	Organisation and function of the gut microbiota in cystic fibrosis (VIA 077)
Edinburgh University	FY2021	£47k	Cystic fibrosis lung repair (VIA 069)
Manchester Metropolitan University	FY2021	£46k	Detection of CF lung pathogens using engineered bacteriophages (VIA045)
Cambridge University	FY2021	£45k	Post-Doctoral Research Associate Machine Learning (VIA038)
Imperial College London	FY2021	£43k	PhD studentship 2 – Air pollution and environmental factors on infection – linking with Registry data (VIA036)
Imperial College London	FY2021	£43k	PhD studentship 1 – Air pollution and environmental factors on infection – linking with Registry data (VIA035)
University of Cambridge	FY2021	£40k	Technologies for an in-vitro carbon copy of lung disease (VIA 094)
Imperial College London	FY2021	£38k	FREAL – Fungal Resistance Evolution and Acquisition in chronic Lung disease (VIA 081)
Papworth Hospital	FY2021	£36k	The use of breath volatile organic compounds (VOCs) in early detection of acute pulmonary exacerbations in cystic fibrosis (VIA 072)
University of Nottingham	FY2021	£35k	Gut Imaging for Function and Transit in CF – The GIFT Study (VIA061)
University of Manchester	FY2021	£34k	Arthropathy in Adults with cystic fibrosis (VIA064)
University of Cambridge	FY2021	£33k	Tackling CF Lung Infection in vitro: Assessing the Global Impact of Antibiotics on the CF Airway Microflora in a Laboratory Bioreactor (VIA 067)
University of Liverpool	FY2021	£33k	Restoration of luminal fluidity and microbiota in the CF gut (CFGI-SRC) (VIA 079)
Imperial College London/Cycle Pharma	FY2021	£30k	Preclinical testing to repurpose of Glatiramer Acetate (GA) for treatment of Pseudomonas aeruginosa (VIA047)
Imperial College London	FY2021	£30k	Understanding interbacterial competition in the cystic fibrosis lung to identify opportunities for intervention (VIA 070)
University of Copenhagen	FY2021	£27k	Grant to institutions (Note 3b)
University of Copenhagen	FY2021	£27k	‘Co-therapy of a novel Pseudomonas aeruginosa biofilm disruptor with standard of care antibiotics’ (VIA 090)
Bristol University	FY2021	£25k	Dietary manipulation to improve glycaemic control in young people with cystic fibrosis and altered glucose handling: A feasibility study (VIA039)
ECFS	FY2021	£21k	Clinical Trials Network (ECFS-CTN) (VIA 082)
CF Europe	FY2021	£21k	Grant to institutions (Note 3b)
ECFS	FY2021	£21k	Clinical Trials Network (ECFS-CTN) (VIA 071)
ECFS	FY2021	£21k	Clinical Trials Network (ECFS-CTN) (VIA 091)
ECFS	FY2021	£20k	ECFS & CFE Post-Doctoral Research Fellowship (VIA 084)
Diagnostig Ltd	FY2021	£20k	Development of a rapid diagnosis of infection with non-tuberculous mycobacteria in immune-compromised patients (VIA065)
Imperial College London	FY2021	£20k	In the thick of it: Competitive Microbial Interactions in Biofilms (VIA 076)
University of Liverpool	FY2021	£19k	A randomised registry-based open label study to assess change in respiratory function for people with cystic fibrosis (pwCF) with one or two Phe508del variants established on triple CFTR modulator combination therapy after rationalisation of muco-active aerosolised therapies (the CF STORM study) (VIA 088)
Queen’s University Belfast	FY2021	£17k	Grant to institutions (Note 3b)
Imperial College London	FY2021	£15k	Development and validation of the use of videogames and virtual reality to enable autonomous remote monitoring of ototoxicity in high-risk population groups (VIA 093)
Queen's University Belfast	FY2021	£15k	The ubiquitylation system as a therapeutic target in CF (VIA 092)
MRC	FY2021	£3k	Grant to institutions (Note 3b)
University of Cambridge	FY2021	£3k	Screening natural antibiotics against Mycobacterium abscessus (VIA 087)
Cardiff University	FY2021	£2k	Grant to institutions (Note 3b)
University of Edinburgh	FY2021	£2k	Grant to institutions (Note 3b)
University of Birmingham	FY2021	£2k	Grant to institutions (Note 3b)
Great North Children’s Hospital	FY2021	£2k	Grant to institutions (Note 3b)
St George’s University of London	FY2021	£2k	Grant to institutions (Note 3b)
Institute of Cancer Sciences, Glasgow	FY2021	£2k	Grant to institutions (Note 3b)
University of Exeter	FY2021	£2k	Grant to institutions (Note 3b)
Queen's University Belfast	FY2021	£2k	Summer Studentship (Miss Orla Fanthorpe)
University of Bristol	FY2021	£2k	Summer Studentship (Miss Isobel Davis)
University of Edinburgh	FY2021	£2k	Summer Studentship (Miss Loren Hunt)
University of Exeter	FY2021	£2k	Summer Studentship (Mr Henry Phillips)
Newcastle University	FY2021	£2k	Summer Studentship (Mr Robbie Bain)

About this data

This grant list is extracted by automated reading of the grant-maker’s own accounts PDFs as filed with the Charity Commission, and cross-checked against the accounts’ stated grant totals (listed sum 12054907 vs reference 1379000 (774.2% diff; ref=stated)). Recipients are linked to register entries only on an exact charity-number or unambiguous exact-name match. If you represent this funder or a recipient and want a correction, email [email protected].